Atlas Trials

Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)

Clinical trial NCT07573436 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07573436
Sponsor
University of Utah
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Post-transplant Lymphoproliferative Disorder
Start date
2026-08-01
Primary completion
2030-06-01
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.